Navigation Links
Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkin's Lymphoma Presented at ASH Meeting
Date:12/13/2011

x Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401 (
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
5. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
8. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
9. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
10. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  BC Technical, the nation,s leading ... Valley Medical Systems, one of the largest MRI service ... of Ohio Valley Medical Systems allows BC Technical to ... MRI.   "We couldn,t be more excited ... and CEO of BC Technical. "The Ohio Valley engineers ...
(Date:8/3/2015)... Pa. , Aug. 3, 2015 ... specialty biotechnology company focused on developing aerosolized KL4 ... live teleconference and webcast at 8:30 a.m. Eastern Time ... management will discuss the 2015 second quarter financial ... company will issue a press release announcing the ...
(Date:8/3/2015)... Calif., Aug. 3, 2015  DURECT Corporation (Nasdaq: DRRX ... 2015.  Total revenues were $4.4 million and net loss was ... as compared to total revenues of $4.6 million and net ... 30, 2014.At June 30, 2015, we had cash and investments ... million at December 31, 2014.  At June 30, 2015, we ...
Breaking Medicine Technology:BC Technical Acquires Ohio Valley Medical Systems 2Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10
... Inc. (Nasdaq: VRUS ), a clinical stage ... drugs to treat viral infections, today reported financial results ... 2011. Financial ResultsRevenues were $0.2 ... to $0.2 million for the quarter ended June 30, ...
... Md., July 25, 2011 Science, public health, and ... in this document is designed for credentialed journalists. Release dates ... 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... regulatory or enforcement actions due to legal limitations. ...
Cached Medicine Technology:Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 2Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 3Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 4Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 5FDA News & Notes - Week of July 25, 2011 2FDA News & Notes - Week of July 25, 2011 3FDA News & Notes - Week of July 25, 2011 4
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... One of ... interviews to discuss his new book, The Pain Antidote , which provides strategies ... of Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction ...
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye ... entering kindergarten. All required immunizations are covered for members under the Healthchek program ... who aren’t caught up with their immunizations may not be allowed to attend ...
(Date:8/4/2015)... ... 04, 2015 , ... Patients are invited to take advantage ... renowned Beverly Hills facelift surgeon , Dr. Paul Nassif. The opportunity to ... to achieve an outer appearance that meets their personal goals. This consultation with ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s been called “cosmetics heaven,” “mecca for make-up,” ... Naimie’s Beauty Center in LA. Now MENAJI is part of that experience acting as ... Beauty Center has been a favorite of makeup artists and hair pros as well ...
(Date:8/4/2015)... ... 2015 , ... Driving skills may decline with age, but ... August 2015 Harvard Health Letter. , "Age and health conditions aren't enough to ... of skills," says Lissa Kapust, a social worker at Harvard-affiliated Beth Israel Deaconess ...
Breaking Medicine News(10 mins):Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2
... Diane E. Meier, MD, Points to Workforce and Non-Hospice Palliative ... DeParle, Director of the White House Office of Health Reform, ... House health care stakeholder discussions with physicians on Thursday, June ... Meier, MD, was asked to join the discussion focused on ...
... ... adoption during June, which is Adopt-A-Shelter-Cat Month. Pregnancy and cats need not be ... ... owners who are looking to adopt a cat during Adopt-A-Shelter-Cat-Month in June should not ...
... , Patient Care Will be Degraded by End of ... Geri Jenkins, RN, co-President of the National Nurses ... Union -- issued the following statement in reaction to ... attempts to strip employees of their employer-provided health coverage, ...
... and BUDAPEST, Hungary, June 18 KV Pharmaceutical Company ... an agreement with Gedeon Richter, Plc. of Budapest, Hungary, ... to certain of KV,s technologies and products in Women,s ... Gedeon Richter rights to manufacture and distribute certain of ...
... ... it could mean that prescription drug abuse among teenagers is on the rise.,TestCountry.com, a leading ... drug test panels, particularly those used for determining prescription drug abuse in teenagers. , ... San Diego, CA (PRWeb) June 18,2009 ...
... need to get on list quickly, experts say, , THURSDAY, ... people over the age of 60 who are hoping for ... new research shows. , The study also found that other ... types, being older than 70, or waiting for a transplant ...
Cached Medicine News:Health News:White House Health Reform Stakeholder Discussion Brings Palliative Care to the Table 2Health News:Fears About Pregnancy and cats Should not stop Those who want to Adopt a cat 2Health News:Fears About Pregnancy and cats Should not stop Those who want to Adopt a cat 3Health News:KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter 2Health News:KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter 3Health News:KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter 4Health News:KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter 5Health News:Is Your Teenager Using Prescription Drugs Behind Your Back?,TestCountry Drug Test Panel Numbers Tally with NIDA Fact Sheet Reports on Prescription Drug A 2Health News:Is Your Teenager Using Prescription Drugs Behind Your Back?,TestCountry Drug Test Panel Numbers Tally with NIDA Fact Sheet Reports on Prescription Drug A 3Health News:Almost Half of Those Over 60 Die While Waiting for Kidney Transplant 2Health News:Almost Half of Those Over 60 Die While Waiting for Kidney Transplant 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: